RECURRENT CLASSIC HODGKIN LYMPHOMA
Clinical trials for RECURRENT CLASSIC HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CLASSIC HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT CLASSIC HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Triple-Drug attack shows promise for tough hodgkin lymphoma cases
Disease control OngoingThis study tests a combination of three drugs (ipilimumab, nivolumab, and brentuximab vedotin) in people with Hodgkin lymphoma that has come back or not responded to prior treatment. The goal is to find the safest doses and see how well the drugs work together to shrink tumors. A…
Matched conditions: RECURRENT CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New drug combo shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-stage study tested a combination of two drugs—pembrolizumab (an immunotherapy) and vorinostat (a targeted therapy)—in 52 adults with certain types of lymphoma that had returned or stopped responding to standard treatments. The main goals were to find the safest dose of…
Matched conditions: RECURRENT CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC